HBV Poblaciones Especiales CCO JUN 2014

8/10/2019 HBV Poblaciones Especiales CCO JUN 2014

1/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Supporting-Assets.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-7.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-6.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-5/Subpage-3.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-5/Subpage-2.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-5/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-5.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-4/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-4.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-6.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-5.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-4.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-3.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-2.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2/Subpage-3.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2/Subpage-2.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Summary.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations.aspx?view=updatesummaryhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations.aspx?view=authorinfohttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations.aspx


2/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hollinger%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Squadrito%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cacciola%201999?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hytiroglou%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lee%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chang%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Marcellin%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wit%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Thio%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weber%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202006?view=token


3/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hyams%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hyams%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Sinicco%201997?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Gatanaga%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Bodsworth%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hadler%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Sanchez%202014?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pittman%202014?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pittman%202014?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Freitas%202014?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Alter%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hughes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fattovich%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ohkawa%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zarski%201998?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=token


4/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Miailhes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Bottero%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chang%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Marcellin%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Thio%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wit%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Thio%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Thio%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weber%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20nonrandomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Di%20Martino%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Bodsworth%201989?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Colin%201999?view=token


5/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EACS%20ART?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EACS%20ART?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/DHHS%20ART?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Benhamou%202000?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EACS%20ART?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/DHHS%20ART?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=token


6/56


7/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tyson%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tyson%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Textbooks/HIV/Management_of_Specific_Disease_States/ch36_pt2_Hepatic/Chapter-Pages/Page-4.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EACS%20ART?view=tokenhttp://www.inpractice.com/Resources/Guidelines/HIV/Antiretroviral%20Management/Guidelines%20for%20the%20Clinical%20Management?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Benhamou%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/DHHS%20ART?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Di%20Martino%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Sasadeusz%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/McMahon%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EACS%20ART?view=tokenhttp://www.inpractice.com/Resources/Guidelines/HIV/Antiretroviral%20Management/Guidelines%20for%20the%20Clinical%20Management?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/DHHS%20ART?view=tokenhttp://www.inpractice.com/Resources/Guidelines/HIV/Antiretroviral%20Management/US%20DHHS?view=token


8/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liu%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Jamma%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telaprevir?view=tokenhttp://www.inpractice.com/Resources/Drugs/b/boceprevir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liu%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liu%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Macas%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ohkawa%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zarski%201998?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Schuttler%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hollinger%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Squadrito%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cacciola%201999?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cacciola%201999?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hytiroglou%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lee%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dai%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Haushofer%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rautou%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rautou%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=token


9/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hughes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Farci%202003?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Jamma%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%202008?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liu%202007?view=token


10/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hughes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hughes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chen%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yurdaydin%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Niro%202006?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/ribavirin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hughes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wedemeyer%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wedemeyer%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Farci%201994?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Farci%201994?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Niro%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Gish%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fattovich%202000?view=token


11/56
http://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch6_Hep_Delta_Infection.aspx


12/56
http://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lao%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rawal%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yang%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Terrault%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chang%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202008?view=token


13/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/CDC%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20uncontrolled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hu%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pan%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zou%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/van%20Zonneveld%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Xu%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Burk%201994?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-3.aspx


14/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Giles%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Kim%202013a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tan%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/CDC%20Immunization%20Strategy?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/CDC%20Immunization%20Strategy?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/P/Peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Telbivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20nonrandomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/L/Lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-3.aspxhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=token


15/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Buster%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chu%201985?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Chang%201995?view=token


16/56
http://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lao%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lao%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rawal%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yang%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Terrault%202007?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=token


17/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch3_Hep_B_Epidemiology_Pathogenesis_Diagnosis_and_Natural_History/Chapter-Pages/Page-3/Subpage-7.aspx


18/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Burk%201994?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Burk%201994?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/van%20Zonneveld%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Xu%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Burk%201994?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20nonrandomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/L/Lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/L/Lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/E/Entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/A/Adefovir?view=token


19/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Han%202013b?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Han%202013a?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liu%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pan%202010?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Han%202011?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Xu%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wen%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Burk%201994?view=token


20/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/CDC%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/CDC%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hu%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pan%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zou%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ayers%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yuen%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yuen%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yi%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Greenup%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Celen%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ganne%20Carrie%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=token


21/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/L/Lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-3.aspxhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tran%202009a?view=token


22/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Giles%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Kim%202013a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tan%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/CDC%20Immunization%20Strategy?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202004?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/P/Peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Resources/Drugs/p/peginterferon%20alfa%202a?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pan%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pan%202010?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/telbivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=token


23/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lao%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rawal%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yang%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Terrault%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lao%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rawal%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yang%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Terrault%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Keywords/Pregnancy.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Beasley%201975?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lee%201978?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Carey%202013?view=token


24/56
http://www.inpractice.com/Keywords/Pregnancy.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch3_Hep_B_Epidemiology_Pathogenesis_Diagnosis_and_Natural_History/Chapter-Pages/Page-3/Subpage-7.aspxhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Keywords/Pregnancy.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lao%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tse%202005?view=token


25/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%201999?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weinbaum%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weinbaum%202008?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Surveillance/CDC%20Chronic%20HEP%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zhong%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Park%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Park%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Moses%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Vassilopoulos%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rutgeerts%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/alemtuzumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Roche%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Feld%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Feld%202010?view=token


26/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zhong%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/o/ofatumumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Resources/Drugs/o/ofatumumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Resources/Drugs/o/ofatumumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/FDA%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/o/ofatumumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/FDA%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Moses%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/alemtuzumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/o/ofatumumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cheng%201996?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Park%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Moses%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Vassilopoulos%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Vassilopoulos%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rutgeerts%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Roche%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Feld%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Feld%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=token


27/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Huang%202013a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Huang%202013a?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lubel%202010?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Westhoff%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Westhoff%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Sarrecchia%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dervite%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Sera%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Law%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weinbaum%202008?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Surveillance/CDC%20Chronic%20HEP%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/AASLD%20Hep%20B?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ling%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/d/doxorubicin?view=tokenhttp://www.inpractice.com/Resources/Drugs/i/infliximab?view=tokenhttp://www.inpractice.com/Resources/Drugs/i/infliximab?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adalimumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/etanercept?view=tokenhttp://www.inpractice.com/Resources/Drugs/i/infliximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/PrezAlvarez%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Carroll%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20uncontrolled%20study?view=token


28/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lubel%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Vassiliadis%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%202000?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lubel%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Seto%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Huang%202013b?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=token


29/56
http://www.inpractice.com/Resources/Drugs/p/prednisone?view=tokenhttp://www.inpractice.com/Resources/Drugs/v/vincristine?view=tokenhttp://www.inpractice.com/Resources/Drugs/d/doxorubicin?view=tokenhttp://www.inpractice.com/Resources/Drugs/c/cyclophosphamide?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.clinicaloptions.com/inPractice/Journal%20Highlights/Hsu_Hepatology_2013/Capsule.aspx?lg=printhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-4/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lim%202002?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Yeo%201999?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Keam%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Long%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lau%202002?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lau%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=token


30/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/A/Adefovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fontana%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fontana%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dienstag%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/L/Lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hoofnagle%201993?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%201995?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tenofovir%20PI?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Entecavir%20PI?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Samuel%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Singal%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Steinmller%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=token


31/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Kim%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Samuel%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20nonrandomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Singal%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Jiang%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Steinmller%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20cohort%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lake%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Steinmller%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Todo%201991?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Steinmller%202002?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=token


32/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Gracey%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cooper%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Kohler%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tenofovir%20PI?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Entecavir%20PI?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tenofovir%20PI?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tenofovir%20PI?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine%20tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202011b?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202011b?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Shim%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202011a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202011a?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Entecavir%20PI?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Shim%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202011a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tenney%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Leemans%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lo%202005?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fontana%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dienstag%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dienstag%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fontana%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202003?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Buster%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hoofnagle%201993?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%201995?view=token


33/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Khemichian%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dan%202006?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Saab%202011?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wong%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Saab%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Kim%202013b?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Fung%202011?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Guidelines/Hepatology/Hep%20B/EASL%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Perrillo%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lo%202005?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dumortier%202003?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=token


34/56
http://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Pan%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Prieto%202001?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Munoz%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Munoz%202002?view=tokenhttp://www.clinicaloptions.com/inPractice/Journal%20Highlights/Fung_AJG_2013/Capsule.aspx?lg=printhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine?view=tokenhttp://www.inpractice.com/Resources/Drugs/T/Tenofovir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Teperman%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Teperman%202013?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/emtricitabine?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Jiang%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/L/Lamivudine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Buti%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Buti%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Dodson%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Buti%202003?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/adefovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=token


35/56
http://www.inpractice.com/Keywords/Liver-Transplantation.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Keywords/Advanced-Liver-Disease/Treatment.aspxhttp://www.inpractice.com/Keywords/Advanced-Liver-Disease/Treatment.aspxhttp://www.inpractice.com/Keywords/Advanced-Liver-Disease/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Advanced-Liver-Disease.aspxhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cholongitas%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Domnguez%202000?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20epidemiologic%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cholongitas%202010?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/l/lamivudine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=token


36/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Spiegel%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tran%202009b?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tran%202009b?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APIAHF%20Comm?view=token


37/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Macas%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2/Subpage-2.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ohkawa%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Zarski%201998?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hollinger%202010?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Squadrito%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Cacciola%201999?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hytiroglou%201995?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lee%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202000?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Liaw%202004?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Sasadeusz%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/McMahon%202007?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Wit%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Thio%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weber%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Puoti%202006?view=tokenhttp://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspx


38/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Steinmller%202002?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-4.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Weinbaum%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Park%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Moses%202006?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Vassilopoulos%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Vassilopoulos%202007?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Rutgeerts%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/B%20case%20controlled%20study?view=tokenhttp://www.inpractice.com/Resources/Drugs/a/alemtuzumab?view=tokenhttp://www.inpractice.com/Resources/Drugs/r/rituximab?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Roche%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Giles%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Kim%202013a?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Tan%202008?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/Evidence%20Ratings/A%20strong%20randomized%20trial?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Mast%202005?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20pediatric%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-2/Sub-Subpage-3.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20adult%20vaccine?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-3/Subpage-1.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/Chapter-Pages/Page-2/Subpage-3.aspxhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Hughes%202011?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Lok%202009?view=token


39/56
http://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Ayers%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APRSC%202013?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/APIAHF%20Comm?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/Alter%202006?view=tokenhttp://www.inpractice.com/Keywords/Hepatitis-B/Treatment.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B/Special-Populations.aspxhttp://www.inpractice.com/Keywords/Hepatitis-B.aspxhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Textbooks/Hepatology/ch5_Hep_B_Spec_Populations/References/EASL%20HBV?view=tokenhttp://www.inpractice.com/Resources/Drugs/e/entecavir?view=tokenhttp://www.inpractice.com/Resources/Drugs/t/tenofovir?view=tokenhttp://www.inpractice.com/Resources/Drugs/h/hepatitis%20B%20immune%20globulin?view=tokenhttp://www.inpractice.com/Resources/Drugs/A/Adefovir?view=tok

Documents

HBV Poblaciones Especiales CCO JUN 2014